INVESTORS
A leading antibody innovation powerhouse
We are a leading international biotechnology company with the ambition to continue to improve the lives of patients with cancer by creating and developing innovative antibody products that will transform the treatment of cancer.
By 2025, our vision is that our own product will have transformed cancer treatment and we will have a robust pipeline of next-generation antibodies.
| ||||||||
| ||||||||
Investor Relations Overview
Creating value by turning science into medicine
Our ambition is to develop drug candidates that have the potential to transform cancer treatment. We do so by leveraging the success of our partnered assets and continuing to invest in our novel proprietary pipeline and technology platforms.
Founded in Copenhagen, Denmark in 1999, Genmab A/S’s ordinary shares are listed on the Nasdaq Copenhagen A/S under the ticker symbol GMAB and are traded as part of the OMXC25. Genmab’s American Depositary Shares issued under the ADR Program are listed in the U.S. on the Nasdaq Global Select Market under the ticker symbol GMAB, and the shares are included in the NASDAQ Biotechnology Index (Nasdaq: NBI).
First Half 2021 Financial Results
Genmab will report its financial results for the first half of 2021 on August 11.
Latest news
Events and presentations
Financial Reports
Search and read Genmab’s most recent and previous financial reports.
SEC Filings
See our statements, reports, and other forms submitted to the U.S. Securities and Exchange Commission (SEC).
Corporate Social Responsibility
We are committed to being a sustainable and socially responsible biotech company.
Our Science
Our passion for innovation is driven by data and rooted in science.
The Pipeline
See the results of our innovation that is driven by data.
Governance Overview
Our commitment to corporate governance is based on ethics and integrity.
Investor inquiries
Our aim is to deliver reliable and transparent information to our shareholders. If you have questions about Genmab, our products or other relevant shareholder information, please use the information below to contact us. We will handle your personal data in accordance with our Privacy Policy.
Marisol Peron
Senior Vice President, Global Communications & Investor Relations
Telephone: + 1 609 524 0065
Email: [email protected]
777 Scudders Mill Road
Plainsboro, NJ 08536
USA
Andrew Carlsen
Vice President,
Head of Investor RelationsTelephone: +45 3377 9558
Email: [email protected]
Kalvebod Brygge 43
1560 Copenhagen V
Denmark
Examine key figures
See snapshots of our balance sheets,
cash flow and other statementsVisit the investor library
Access our financial reports, webcasts, presentations and more
Stay informed
Sign up to receive email alerts with
our latest news